

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT4337482

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	SANOFI	09/17/2015
RECEIVING PARTY DATA		
Name:	SANOFI BIOTECHNOLOGY	
Street Address:	54 RUE LA BOETIE	
City:	PARIS	
State/Country:	FRANCE	
Postal Code:	75008	
PROPERTY NUMBERS Total: 1		
Property Type	Number	
Application Number:	14896196	
CORRESPONDENCE DATA		
Fax Number:	(908)981-7832	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	617-768-6945	
Email:	globalpatent.eflow@sanofi.com	
Correspondent Name:	LEA R. JAYME	
Address Line 1:	55 CORPORATE DRIVE	
Address Line 2:	MAIL CODE: 55A-505A	
Address Line 4:	BRIDGEWATER, NEW JERSEY 08807	
ATTORNEY DOCKET NUMBER:	US2013/205 USPCT	
NAME OF SUBMITTER:	LEA R. JAYME	
SIGNATURE:	/Lea R. Jayme/	
DATE SIGNED:	03/27/2017	
Total Attachments: 17		
source=US2013-205_Sanofi to Sanofi Biotechnolgy Assignment#page1.tif		
source=US2013-205_Sanofi to Sanofi Biotechnolgy Assignment#page2.tif		
source=US2013-205_Sanofi to Sanofi Biotechnolgy Assignment#page3.tif		
source=US2013-205_Sanofi to Sanofi Biotechnolgy Assignment#page4.tif		
source=US2013-205_Sanofi to Sanofi Biotechnolgy Assignment#page5.tif		

source=US2013-205_Sanofi to Sanofi Biotechnolgy Assignment#page6.tif
source=US2013-205_Sanofi to Sanofi Biotechnolgy Assignment#page7.tif
source=US2013-205_Sanofi to Sanofi Biotechnolgy Assignment#page8.tif
source=US2013-205_Sanofi to Sanofi Biotechnolgy Assignment#page9.tif
source=US2013-205_Sanofi to Sanofi Biotechnolgy Assignment#page10.tif
source=US2013-205_Sanofi to Sanofi Biotechnolgy Assignment#page11.tif
source=US2013-205_Sanofi to Sanofi Biotechnolgy Assignment#page12.tif
source=US2013-205_Sanofi to Sanofi Biotechnolgy Assignment#page13.tif
source=US2013-205_Sanofi to Sanofi Biotechnolgy Assignment#page14.tif
source=US2013-205_Sanofi to Sanofi Biotechnolgy Assignment#page15.tif
source=US2013-205_Sanofi to Sanofi Biotechnolgy Assignment#page16.tif
source=US2013-205_Sanofi to Sanofi Biotechnolgy Assignment#page17.tif

ASSIGNMENT AND AGREEMENT

For value received and intending to be legally bound, we, **SANOFI**, of 54 rue La Boétie, 75008 Paris, France, (Assignor), sell, assign and transfer to **SANOFI BIOTECHNOLOGY**, of 54 rue La Boétie, 75008 Paris, France, (Assignee), and its successors, assigns and legal representatives, our entire and exclusive right, title and interest in the patent properties specified in **Exhibit A** attached hereto.

All the rights and privileges, including any and all benefits under the International Convention for the Protection of Industrial Property, including the right to claim priority based on said priority applications, and under any and all Letters Patent which may be granted therefore, and all right, title and interest in and to every patent application filed or to be filed on said invention in any other country or patent organization, including, without limitation, continuations, divisions, renewals, revivals, and any substitute applications of the above applications, and any and all patents which may issue thereon, and any reissues, reexaminations, pipelines and extensions, and governmental exclusivity rights of the same; and we hereby authorize and request the USPTO and any foreign patent authority or office whose duty it is to issue patents on applications or priorities as described above, to issue all Letters Patent for this invention to Assignee, its successors and assigns, in accordance with the terms of this Assignment.


We authorize and request competent authorities to grant and issue any and all patents on said invention to said assignee or its successor, assigns and legal representatives, or to such nominees as said assignee may designate.

We agree that, when requested, we will, without charge to said assignee but at its expense, sign all papers, take all rightful oaths, testify in any legal proceeding, and do all acts which may be necessary, desirable or convenient for securing, maintaining, and enforcing patents for said invention in any and all countries and for vesting title thereto in said assignee, its successors, assigns, legal representatives or nominees.

We covenant with said assignee, its successors, assigns and legal representatives, that the rights and property herein conveyed are free and clear of any encumbrance, and that I/we have full right to convey the same as herein expressed and that I/we will not enter into any assignment, contract, or understanding in conflict herewith.

Signed at Bridgewater, NJ 08807 USA on this 17th day of September, 2015.

SANOFI

By: 
Andrea Q. Ryan
Director, Global Patent Administration
Authorized Signatory


Accepted By:

Signed at Bridgewater, NJ 08807 USA on this 21 day of September, 2015.

SANOFI BIOTECHNOLOGY

By: 
John D. Conway
Vice President, Head of Global IP

Witnesses:


Name: GREET AERSHEY



Name: MARIBEL MENDEZ

EXHIBIT A
(Sanofi to Sanofi Biotechnology)

Sanofi No.	Country	Type	Title	Filing Date	Filing No.	Grant Date	Patent No.	Expiry Date	Status
DE2011/013	AR	NP	Clinical Trial DF11566	27 Jan 2012	P120100275			27 Jan 2032	ABANDONED
DE2011/013	AU	PCT	Clinical Trial DF11566	27 Jan 2012	2012210480			27 Jan 2032	PENDING
DE2011/013	BR	PCT	Clinical Trial DF11566	27 Jan 2012	BR112013018740-9			27 Jan 2032	PENDING
DE2011/013	CA	PCT	Clinical Trial DF11566	27 Jan 2012	2825838			27 Jan 2032	PENDING
DE2011/013	CL	PCT	Clinical Trial DF11566	27 Jan 2012	2013-2161			27 Jan 2032	PENDING
DE2011/013	CN	PCT	Clinical Trial DF11566	27 Jan 2012	201280015477.6			27 Jan 2032	PENDING
DE2011/013	CO	PCT	Clinical Trial DF11566	20 Jun 2013	13203075			27 Jan 2032	ABANDONED
DE2011/013	DZ	PCT	Clinical Trial DF11566	27 Jan 2012	130546			27 Jan 2032	PENDING
DE2011/013	EP	EPA	Clinical Trial DF11566	28 Jan 2011	11305089.2			27 Jan 2032	ABANDONED
DE2011/013	EP	EPT	Clinical Trial DF11566	27 Jan 2012	12701742.4			27 Jan 2032	PENDING
DE2011/013	HK	EKT	Clinical Trial DF11566	28 May 2014	14105033.2			26 Aug 2033	PENDING
DE2011/013	ID	PCT	Clinical Trial DF11566	26 Aug 2013	W-00 2013 03887			27 Jan 2032	PENDING
DE2011/013	IL	PCT	Clinical Trial DF11566	27 Jan 2012	227657			27 Jan 2032	ABANDONED
DE2011/013	IN	PCT	Clinical Trial DF11566	27 Jan 2012	6744/CHENP/2013			27 Jan 2032	PENDING
DE2011/013	JP	PCT	Clinical Trial DF11566	27 Jan 2012	2013-550891			27 Jan 2032	PENDING
DE2011/013	KR	PCT	Clinical Trial DF11566	27 Jan 2012	10-2013-7022848			27 Jan 2032	PENDING
DE2011/013	MA	PCT	Clinical Trial DF11566	27 Jan 2012	36205	01 Feb 2014	34923	27 Jan 2032	GRANTED
DE2011/013	MX	PCT	Clinical Trial DF11566	27 Jan 2012	MX/a/2013/008669			27 Jan 2032	PENDING
DE2011/013	MY	PCT	Clinical Trial DF11566	27 Jan 2012	P12013002724			27 Jan 2032	PENDING
DE2011/013	NZ	Div	Clinical Trial DF11566	02 Sep 2015	711799			27 Jan 2032	PENDING
DE2011/013	NZ	PCT	Clinical Trial DF11566	27 Jan 2012	613867			27 Jan 2032	PENDING
DE2011/013	NZ	PCT	Clinical Trial DF11566	27 Jan 2012	1-2013-501577			27 Jan 2032	PENDING
DE2011/013	PH	PCT	Clinical Trial DF11566	27 Jan 2012	2013139727			27 Jan 2032	PENDING
DE2011/013	RU	PCT	Clinical Trial DF11566	27 Jan 2012	201305643-7			27 Jan 2032	PENDING
DE2011/013	SG	PCT	Clinical Trial DF11566	20 Jun 2013	1301004186			20 Jun 2033	PENDING
DE2011/013	TH	PCT	Clinical Trial DF11566	30 Jan 2012	101102966			29 Jul 2033	ABANDONED
DE2011/013	TW	NP	Clinical Trial DF11566	29 Jul 2013	13/982.373			29 Jul 2033	PENDING
DE2011/013	US	PCT	Clinical Trial DF11566	27 Jan 2012	1-2013-02686			27 Jan 2032	ABANDONED
DE2011/013	VN	PCT	Clinical Trial DF11566	27 Jan 2012	PCT/EP2012/051320			27 Jan 2032	ABANDONED
DE2011/013	WO	PCT	Clinical Trial DF11566	27 Jan 2012	2013/05524	26 Mar 2014	2013/05524	27 Jan 2032	GRANTED
DE2011/013	ZA	PCT	Clinical Trial DF11566	27 Jan 2012	P120100276			27 Jan 2032	PENDING
DE2011/085	AR	NP	Clinical Trial DF11565	27 Jan 2012	2012210481			27 Jan 2032	PENDING
DE2011/085	AU	PCT	Clinical Trial DF11565	27 Jan 2012	BR112013018877-4			27 Jan 2032	PENDING
DE2011/085	BR	PCT	Clinical Trial DF11565	27 Jan 2012	2825778			27 Jan 2032	PENDING
DE2011/085	CA	PCT	Clinical Trial DF11565	27 Jan 2012	2013-2162			27 Jan 2032	PENDING
DE2011/085	CL	PCT	Clinical Trial DF11565	27 Jan 2012	201280015571.1			27 Jan 2032	PENDING
DE2011/085	CN	PCT	Clinical Trial DF11565	27 Jan 2012	13203072			27 Jan 2032	PENDING
DE2011/085	CO	PCT	Clinical Trial DF11565	27 Jan 2012	2013-0406			27 Jan 2032	PENDING
DE2011/085	CR	PCT	Clinical Trial DF11565	27 Jan 2012	P2013-0170			27 Jan 2032	PENDING
DE2011/085	DO	PCT	Clinical Trial DF11565	27 Jan 2012	130545			27 Jan 2032	PENDING
DE2011/085	DZ	PCT	Clinical Trial DF11565	27 Jan 2012	SP-2013-12792			27 Jan 2032	PENDING
DE2011/085	EC	PCT	Clinical Trial DF11565	27 Jan 2012	1235/2013			27 Jan 2032	PENDING
DE2011/085	EG	PCT	Clinical Trial DF11565	29 Apr 2011	11305513.1			27 Jan 2032	ABANDONED
DE2011/085	EP	EPA	Clinical Trial DF11565	27 Jan 2012	12701015.5			27 Jan 2032	PENDING
DE2011/085	EP	EPT	Clinical Trial DF11565	27 Jan 2012	A-2013000186			27 Jan 2032	PENDING
DE2011/085	GT	PCT	Clinical Trial DF11565	27 Jan 2012				27 Jan 2032	PENDING

EXHIBIT A
(Sanofi to Sanofi Biotechnology)

Sanofi No.	Country	Type	Title	Filing Date	Filing No.	Grant Date	Patent No.	Expiry Date	Status
DE2011/085	HK	EXT	Clinical Trial DF11565	28 May 2014	14105032.3			27 Jan 2032	PENDING
DE2011/085	HN	PCT	Clinical Trial DF11565	27 Jan 2012	2013-001746			27 Jan 2032	PENDING
DE2011/085	ID	PCT	Clinical Trial DF11565	27 Jan 2012	W-00 2013 03888			27 Jan 2032	PENDING
DE2011/085	IL	PCT	Clinical Trial DF11565	27 Jan 2012	227658			27 Jan 2032	PENDING
DE2011/085	IN	PCT	Clinical Trial DF11565	27 Jan 2012	6743/CHENP/2013			27 Jan 2032	PENDING
DE2011/085	JP	PCT	Clinical Trial DF11565	27 Jan 2012	2013-550892			27 Jan 2032	PENDING
DE2011/085	KE	PCT	Clinical Trial DF11565	27 Jan 2012	KE/P/2013/001881			27 Jan 2032	PENDING
DE2011/085	KR	PCT	Clinical Trial DF11565	27 Jan 2012	10-2013-7022847			27 Jan 2032	PENDING
DE2011/085	MA	PCT	Clinical Trial DF11565	27 Jan 2012	36190			27 Jan 2032	PENDING
DE2011/085	MX	PCT	Clinical Trial DF11565	27 Jan 2012	MX/a/2013/008672			27 Jan 2032	PENDING
DE2011/085	MY	PCT	Clinical Trial DF11565	27 Jan 2012	P12013002740			27 Jan 2032	PENDING
DE2011/085	NG	PCT	Clinical Trial DF11565	27 Jan 2012	NG/C/2013/559			27 Jan 2032	PENDING
DE2011/085	NI	PCT	Clinical Trial DF11565	27 Jan 2012	2013-000064			26 Jan 2032	PENDING
DE2011/085	NZ	PCT	Clinical Trial DF11565	27 Jan 2012	613870			27 Jan 2032	PENDING
DE2011/085	OA	PCT	Clinical Trial DF11565	27 Jan 2012	1201300310			27 Jan 2032	PENDING
DE2011/085	PE	PCT	Clinical Trial DF11565	27 Jan 2012	001712-2013/DIN			27 Jan 2032	PENDING
DE2011/085	PH	PCT	Clinical Trial DF11565	27 Jan 2012	1-2013-501576			27 Jan 2032	PENDING
DE2011/085	RU	PCT	Clinical Trial DF11565	27 Jan 2012	2013139736			27 Jan 2032	PENDING
DE2011/085	SG	PCT	Clinical Trial DF11565	27 Jan 2012	201305644-5			27 Jan 2032	PENDING
DE2011/085	SV	PCT	Clinical Trial DF11565	27 Jan 2012	2013004505			27 Jan 2032	PENDING
DE2011/085	TH	PCT	Clinical Trial DF11565	27 Jan 2012	1301004187			27 Jan 2032	PENDING
DE2011/085	TN	PCT	Clinical Trial DF11565	27 Jan 2012	TN2013/0322			27 Jan 2032	PENDING
DE2011/085	TW	NP	Clinical Trial DF11565	30 Jan 2012	101102967			29 Jan 2032	PENDING
DE2011/085	UA	PCT	Clinical Trial DF11565	27 Aug 2013	201310463			27 Aug 2033	PENDING
DE2011/085	US	PCT	Clinical Trial DF11565	29 Jul 2013	13/982.381			27 Jan 2032	PENDING
DE2011/085	VN	PCT	Clinical Trial DF11565	27 Jan 2012	1-2013-02685			27 Jan 2032	PENDING
DE2011/085	WO	PCT	Clinical Trial DF11565	27 Jan 2012	PCT/EP2012/051321			27 Jan 2032	ABANDONED
DE2011/085	ZA	PCT	Clinical Trial DF11565	27 Jan 2012	2013/05565			27 Jan 2032	PENDING
DE2012/021	AR	NP	TEST SYSTEMS AND METHODS FOR IDENTIFYING AND CHARACTERISING LIPID LOWERING DRUGS	27 Apr 2012	P120101508			27 Apr 2032	PENDING
DE2012/021	EP	EPA	TEST SYSTEMS AND METHODS FOR IDENTIFYING AND CHARACTERISING LIPID LOWERING DRUGS	27 Jan 2012	12152862.4				ABANDONED
DE2012/021	EP	EPT	TEST SYSTEMS AND METHODS FOR IDENTIFYING AND CHARACTERISING LIPID LOWERING DRUGS	30 Apr 2012	12720471.7			30 Apr 2032	PENDING
DE2012/021	TW	NP	TEST SYSTEMS AND METHODS FOR IDENTIFYING AND CHARACTERISING LIPID LOWERING DRUGS	27 Apr 2012	101115344			26 Apr 2032	PENDING
DE2012/021	US	PCT	TEST SYSTEMS AND METHODS FOR IDENTIFYING AND CHARACTERISING LIPID LOWERING DRUGS	28 Oct 2013	14/114,523			30 Apr 2032	PENDING

EXHIBIT A
(Sanofi to Sanofi Biotechnology)

Sanofi No.	Country	Type	Title	Filing Date	Filing No.	Grant Date	Patent No.	Expiry Date	Status
DE2012/021	WO	PCT	TEST SYSTEMS AND METHODS FOR IDENTIFYING AND CHARACTERISING LIPID LOWERING DRUGS	30 Apr 2012	PCT/EP2012/057890				ABANDONED
US2011/131	AR	NP	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	120103770				ABANDONED
US2011/131	AU	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	2012323062			10 Oct 2032	PENDING
US2011/131	BO	NP	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	SP-0361-2012				ABANDONED
US2011/131	BR	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	112014008764-4			10 Oct 2032	PENDING
US2011/131	CA	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	2.851.751			10 Oct 2032	PENDING
US2011/131	CL	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	00926-2014			10 Oct 2032	PENDING
US2011/131	CN	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	201280060133.7			10 Oct 2032	PENDING
US2011/131	CO	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	14099490				ABANDONED
US2011/131	DZ	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	PCT/EP2012/070052			10 Oct 2032	PENDING
US2011/131	EP	EPA	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	20 Jul 2012	12305889.3			20 Jul 2032	PENDING
US2011/131	EP	EPT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	12769684.7			10 Oct 2032	PENDING
US2011/131	GC	NP	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	09 Oct 2012	2012/22496			09 Oct 2032	PENDING
US2011/131	HK	EBE	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	03 Sep 2014	14108937.3			10 Oct 2032	PENDING
US2011/131	ID	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	P-00201402778			10 Oct 2032	PENDING

EXHIBIT A
(Sanofi to Sanofi Biotechnology)

Sanofi No.	Country	Type	Title	Filing Date	Filing No.	Grant Date	Patent No.	Expiry Date	Status
US2011/131	IL	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	232001			10 Oct 2032	PENDING
US2011/131	IN	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	987/KOLNP/2014				ABANDONED
US2011/131	JO	NP	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	09 Oct 2012	304/2012				ABANDONED
US2011/131	JP	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	2014-535044			10 Oct 2032	PENDING
US2011/131	KR	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	10-2014-7012534			10 Oct 2032	PENDING
US2011/131	LB	NP	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	11 Oct 2012	9805				ABANDONED
US2011/131	MA	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	36969			10 Oct 2032	PENDING
US2011/131	MX	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	MX/a/2014/004398			10 Oct 2032	PENDING
US2011/131	MY	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	PI 2014001045			10 Oct 2032	PENDING
US2011/131	NZ	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	623815			10 Oct 2032	PENDING
US2011/131	PH	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	1-2014-500784			10 Oct 2032	PENDING
US2011/131	PK	NP	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	09 Oct 2012	682/2012				ABANDONED
US2011/131	PY	NP	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	11 Oct 2012	47978/2012				ABANDONED
US2011/131	RU	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	2014118741			10 Oct 2032	PENDING
US2011/131	SG	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	11201401373R			10 Oct 2032	PENDING

EXHIBIT A
(Sanofi to Sanofi Biotechnology)

Sanofi No.	Country	Type	Title	Filing Date	Filing No.	Grant Date	Patent No.	Expiry Date	Status
US2011/131	TH	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	1401001987			10 Oct 2032	PENDING
US2011/131	TW	NP	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	09 Oct 2012	101137198			08 Oct 2032	PENDING
US2011/131	US	NP	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	13/648,521			10 Oct 2032	PENDING
US2011/131	US	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	14/350,973			10 Oct 2032	PENDING
US2011/131	US	PSP	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	11 Oct 2011	61/545864			11 Oct 2012	PENDING
US2011/131	UY	NP	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	11 Oct 2012	34.387				ABANDONED
US2011/131	VE	NP	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	05 Oct 2012	1360-12				ABANDONED
US2011/131	VN	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	1-2014-01534				ABANDONED
US2011/131	WO	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	PCT/EP2012/070052				ABANDONED
US2011/131	ZA	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	10 Oct 2012	2014/03282			10 Oct 2032	PENDING
US2012/080	AR	NP	ANTH-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	20 Aug 2013	P130102945			20 Aug 2033	PENDING
US2012/080	AU	PCT	ANTH-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	20 Aug 2013	2013305945			20 Aug 2033	PENDING
US2012/080	BO	NP	ANTH-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	21 Aug 2013	SP-0265-2013			21 Aug 2033	PENDING
US2012/080	BR	PCT	ANTH-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	20 Aug 2013	BR112015003590-6			20 Aug 2033	PENDING
US2012/080	CA	PCT	ANTH-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	20 Aug 2013	2882416			20 Aug 2033	PENDING

EXHIBIT A
(Sanofi to Sanofi Biotechnology)

Sanofi No.	Country	Type	Title	Filing Date	Filing No.	Grant Date	Patent No.	Expiry Date	Status
US2012/080	CN	PCT	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	20 Aug 2013	201380054/10.6			20 Aug 2033	PENDING
US2012/080	EP	EPT	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	20 Aug 2013	13759908.0			20 Aug 2033	PENDING
US2012/080	FR	NP	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	16 Jul 2013	1356994				ABANDONED
US2012/080	GC	NP	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	21 Aug 2013	2013/25194			21 Aug 2033	PENDING
US2012/080	IL	PCT	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	20 Aug 2013	237258			20 Aug 2033	PENDING
US2012/080	IN	PCT	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	20 Aug 2013	414/KOLNP/2015			20 Aug 2033	PENDING
US2012/080	JO	NP	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	14 Aug 2013	242/2013				ABANDONED
US2012/080	JP	PCT	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	20 Aug 2013	2015-528576			20 Aug 2033	PENDING
US2012/080	KR	PCT	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	20 Aug 2013	10-2015-7005821			20 Aug 2033	PENDING
US2012/080	LB	NP	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	21 Aug 2013	10100			21 Aug 2033	PENDING
US2012/080	MX	PCT	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	20 Aug 2013	MX/a/2015/002292			20 Aug 2033	PENDING
US2012/080	NZ	PCT	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	20 Aug 2013	631562			20 Aug 2033	PENDING
US2012/080	PK	NP	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	19 Aug 2013	549/2013			21 Aug 2032	PENDING
US2012/080	PY	NP	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	20 Aug 2013	37526/2013			20 Aug 2033	PENDING
US2012/080	RU	PCT	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	20 Aug 2013	2015109716			20 Aug 2033	PENDING

EXHIBIT A
(Sanofi to Sanofi Biotechnology)

Sanofi No.	Country	Type	Title	Filing Date	Filing No.	Grant Date	Patent No.	Expiry Date	Status
US2012/080	SG	PCT	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	20 Aug 2013	1120150089T			20 Aug 2033	PENDING
US2012/080	TW	NP	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	20 Aug 2013	102129743			19 Aug 2033	PENDING
US2012/080	US	NP	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	20 Aug 2013	13/971,334			20 Aug 2033	PENDING
US2012/080	US	PSP	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	29 Jan 2013	61/758,097			29 Jan 2014	Expired
US2012/080	US	PSP	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	27 Mar 2013	61/805,797			27 Mar 2014	Expired
US2012/080	US	PSP	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	21 Aug 2012	61/691,625			21 Aug 2013	Expired
US2012/080	US	PSP	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	14 Mar 2013	61/783,796			14 Mar 2014	Expired
US2012/080	US	PSP	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	06 Feb 2013	61/761,279			06 Feb 2014	Expired
US2012/080	UY	NP	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	21 Aug 2013	34.984			21 Aug 2033	PENDING
US2012/080	VE	NP	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	21 Aug 2013	1055-13			21 Aug 2033	PENDING
US2012/080	WO	PCT	ANTI-IL-4R ANTIBODY ASTHMA CLINICAL TRIAL APPLICATION	20 Aug 2013	PCT/US2013/055747				ABANDONED
US2012/101	AR	NP	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	06 Sep 2013	P130103184			06 Sep 2033	PENDING
US2012/101	AU	PCT	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	04 Sep 2013	2013312868			04 Sep 2033	PENDING
US2012/101	BO	NP	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	06 Sep 2013	SP-00278-2013			06 Sep 2033	PENDING
US2012/101	BR	PCT	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	04 Sep 2013	BR112015005048-4			04 Sep 2033	PENDING

EXHIBIT A
(Sanofi to Sanofi Biotechnology)

Sanofi No.	Country	Type	Title	Filing Date	Filing No.	Grant Date	Patent No.	Expiry Date	Status
US2012/101	CA	PCT	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	04 Sep 2013	2883936			04 Sep 2033	PENDING
US2012/101	CN	PCT	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	04 Sep 2013	201380046623.6			04 Sep 2033	PENDING
US2012/101	EP	EPT	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	04 Sep 2013	13765844.9			04 Sep 2033	PENDING
US2012/101	FR	NP	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	10 Jul 2013	1356759				ABANDONED
US2012/101	GC	NP	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	05 Sep 2013	2013/25319			05 Sep 2033	PENDING
US2012/101	IL	PCT	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	04 Sep 2013	237328			04 Sep 2033	PENDING
US2012/101	IN	PCT	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	04 Sep 2013	916/CHENP/2015			04 Sep 2033	PENDING
US2012/101	JO	NP	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	22 Aug 2013	255/2013				ABANDONED
US2012/101	JP	PCT	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	04 Sep 2013	2015-531149			04 Sep 2033	PENDING
US2012/101	KR	PCT	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	04 Sep 2013	10-2015-7008872			04 Sep 2033	PENDING
US2012/101	LB	NP	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	06 Sep 2013	10118			06 Sep 2033	PENDING
US2012/101	MX	PCT	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	04 Sep 2013	MX/a/2015/002873			04 Sep 2033	PENDING
US2012/101	NZ	PCT	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	04 Sep 2013	630178			04 Sep 2033	PENDING
US2012/101	PK	NP	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	27 Aug 2013	569/2013			07 Sep 2032	PENDING
US2012/101	PY	NP	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	06 Sep 2013	41008/2013			06 Sep 2033	PENDING

EXHIBIT A
(Sanofi to Sanofi Biotechnology)

Sanofi No.	Country	Type	Title	Filing Date	Filing No.	Grant Date	Patent No.	Expiry Date	Status
US2012/101	RU	PCT	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	04 Sep 2013	2015108073			04 Sep 2033	PENDING
US2012/101	SG	PCT	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	04 Sep 2013	11201501011W			04 Sep 2033	PENDING
US2012/101	TW	NP	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	05 Sep 2013	102131927			04 Sep 2033	PENDING
US2012/101	US	NP	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	04 Sep 2013	14/017,333			04 Sep 2033	PENDING
US2012/101	US	PSP	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	27 Feb 2013	61/770,091			27 Feb 2014	Expired
US2012/101	US	PSP	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	03 Jan 2013	61/748,588			03 Jan 2014	Expired
US2012/101	US	PSP	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	22 Feb 2013	61/768,229			22 Feb 2014	Expired
US2012/101	US	PSP	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	26 Apr 2013	61/816,191			26 Apr 2014	Expired
US2012/101	US	PSP	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	18 Dec 2012	61/738,715			18 Dec 2013	Expired
US2012/101	US	PSP	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	14 Mar 2013	61/782,420			14 Mar 2014	Expired
US2012/101	US	PSP	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	14 Feb 2013	61/764,624			14 Feb 2014	Expired
US2012/101	US	PSP	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	07 Sep 2012	61/697,972			07 Sep 2013	Expired
US2012/101	UY	NP	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	06 Sep 2013	35013			06 Sep 2033	PENDING
US2012/101	VE	NP	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	04 Sep 2013	1131-13			04 Sep 2033	PENDING
US2012/101	WO	PCT	METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST	04 Sep 2013	PCT/US2013/057898			04 Sep 2033	PENDING

EXHIBIT A
(Sanofi to Sanofi Biotechnology)

Sanofi No.	Country	Type	Title	Filing Date	Filing No.	Grant Date	Patent No.	Expiry Date	Status
US2013/205	AR	NP	PCSK9	06 Jun 2014	P140102208			06 Jun 2034	PENDING
US2013/205	BO	NP	PCSK9						ABANDONED
US2013/205	EP	EPA	PCSK9	07 Jun 2013	13305762.0				ABANDONED
US2013/205	EP	EPA	PCSK9	18 Oct 2013	13306436.0			18 Oct 2033	PENDING
US2013/205	GC	NP	PCSK9						ABANDONED
US2013/205	JO	NP	PCSK9						ABANDONED
US2013/205	LB	NP	PCSK9						ABANDONED
US2013/205	PK	NP	PCSK9						ABANDONED
US2013/205	PY	NP	PCSK9						ABANDONED
US2013/205	TW	NP	PCSK9	06 Jun 2014	103119641			05 Jun 2034	PENDING
US2013/205	US	PSP	PCSK9	26 Feb 2014	61/944,855			26 Feb 2015	Expired
US2013/205	US	PSP	PCSK9	07 Jun 2013	61/832,459			07 Jun 2014	Expired
US2013/205	US	PSP	PCSK9	23 May 2014	62/002,508			23 May 2015	Expired
US2013/205	US	PSP	PCSK9	17 Oct 2013	61/892215			17 Oct 2014	Expired
US2013/205	UY	NP	PCSK9						ABANDONED
US2013/205	VE	NP	PCSK9						ABANDONED
US2013/205	WO	PCT	PCSK9						PENDING
US2013/210	AR	NP	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS	06 Jun 2014	PCT/US2014/041204			06 Jun 2034	ABANDONED
US2013/210	AU	PCT	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS						TO BE FILED
US2013/210	BR	PCT	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS						TO BE FILED
US2013/210	CA	PCT	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS						TO BE FILED
US2013/210	CN	PCT	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS						TO BE FILED
US2013/210	EP	EPA	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS	07 May 2014	14305670.3			07 May 2034	PENDING
US2013/210	EP	EPT	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS						TO BE FILED
US2013/210	IL	PCT	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS						TO BE FILED
US2013/210	IN	PCT	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS						TO BE FILED
US2013/210	JP	PCT	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS						TO BE FILED
US2013/210	KR	PCT	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS						TO BE FILED
US2013/210	MX	PCT	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS						TO BE FILED
US2013/210	NZ	PCT	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS	20 Jun 2014	631118			20 Jun 2034	PENDING
US2013/210	PK	NP	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS						ABANDONED

EXHIBIT A
(Sanofi to Sanofi Biotechnology)

Sanofi No.	Country	Type	Title	Filing Date	Filing No.	Grant Date	Patent No.	Expiry Date	Status
US2013/210	RU	PCT	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS						TO BE FILED
US2013/210	SG	PCT	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS						TO BE FILED
US2013/210	TW	NP	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS	20 Jun 2014	103121405			19 Jun 2034	PENDING
US2013/210	US	NP	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS	20 Jun 2014	14/310,419			20 Jun 2034	PENDING
US2013/210	US	PSP	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS	21 Jun 2013	61/837,912			21 Jun 2014	Expired
US2013/210	UY	NP	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS						ABANDONED
US2013/210	VE	NP	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS						ABANDONED
US2013/210	WO	PCT	ANTI-IL-4R ANTIBODY TO TREAT NASAL POLYPOSIS	20 Jun 2014	PCT/US2014/043440			20 Jun 2034	PENDING
US2013/257	EP	EPA	METHODS FOR REDUCING CHOLESTEROL BY ADMINISTERING A PCSK9 ANTAGONIST AS A MONOTHERAPY	31 Jul 2014	14306221.4				ABANDONED
US2013/257	TW	NP	METHODS FOR REDUCING CHOLESTEROL BY ADMINISTERING A PCSK9 ANTAGONIST AS A MONOTHERAPY	13 Oct 2014	103135495			12 Oct 2034	PENDING
US2013/257	US	NP	METHODS FOR REDUCING CHOLESTEROL BY ADMINISTERING A PCSK9 ANTAGONIST AS A MONOTHERAPY	10 Oct 2014	14/511,975			10 Oct 2034	PENDING
US2013/257	US	PSP	METHODS FOR REDUCING CHOLESTEROL BY ADMINISTERING A PCSK9 ANTAGONIST AS A MONOTHERAPY	29 May 2014	62/004,620			29 May 2015	Expired
US2013/257	US	PSP	METHODS FOR REDUCING CHOLESTEROL BY ADMINISTERING A PCSK9 ANTAGONIST AS A MONOTHERAPY	19 Mar 2014	61/955,514			19 Mar 2015	Expired
US2013/257	US	PSP	METHODS FOR REDUCING CHOLESTEROL BY ADMINISTERING A PCSK9 ANTAGONIST AS A MONOTHERAPY	11 Oct 2013	61/890154			11 Oct 2014	Expired
US2013/257	US	PSP	METHODS FOR REDUCING CHOLESTEROL BY ADMINISTERING A PCSK9 ANTAGONIST AS A MONOTHERAPY	16 Jun 2014	62/012,839			16 Jun 2015	Expired
US2013/257	US	PSP	METHODS FOR REDUCING CHOLESTEROL BY ADMINISTERING A PCSK9 ANTAGONIST AS A MONOTHERAPY	02 Jan 2014	61/923,103			02 Jan 2015	Expired
US2013/257	WO	PCT	METHODS FOR REDUCING CHOLESTEROL BY ADMINISTERING A PCSK9 ANTAGONIST AS A MONOTHERAPY	10 Oct 2014	PCT/US2014/060109			10 Oct 2034	PENDING
US2013/275	EP	EPA	MONOTHERAPY METHODS AND USES OF ANTI-PCSK9 ANTIBODIES	31 Jul 2014	14306222.2				ABANDONED

EXHIBIT A
(Sanofi to Sanofi Biotechnology)

Sanofi No.	Country	Type	Title	Filing Date	Filing No.	Grant Date	Patent No.	Expiry Date	Status
US2013/275	TW	NP	METHODS AND USES OF ANTI-PCSK9 ANTIBODIES	12 Nov 2014	103139157			11 Nov 2034	PENDING
US2013/275	US	NP	METHODS AND USES OF ANTI-PCSK9 ANTIBODIES	12 Nov 2014	14/539,199			12 Nov 2034	PENDING
US2013/275	US	PSP	METHODS AND USES OF ANTI-PCSK9 ANTIBODIES	19 Mar 2014	61/955,337			19 Mar 2015	Expired
US2013/275	US	PSP	METHODS AND USES OF ANTI-PCSK9 ANTIBODIES	12 Nov 2013	61/902,857			12 Nov 2014	Expired
US2013/275	WO	PCT	METHODS AND USES OF ANTI-PCSK9 ANTIBODIES	12 Nov 2014	PCT/US2014/065149			12 Nov 2034	PENDING
US2013/276	EP	EPA	SARILUMAB (ANTI-IL6R) BIOMARKER	05 Nov 2014	14306771.8				ABANDONED TO BE FILED
US2013/276	TW	NP	SARILUMAB (ANTI-IL6R) BIOMARKER	29 Jan 2014	61/933,156			29 Jan 2015	Expired
US2013/276	US	PSP	SARILUMAB (ANTI-IL6R) BIOMARKER	13 Jun 2014	62/011,675			13 Jun 2015	Expired
US2013/276	US	PSP	SARILUMAB (ANTI-IL6R) BIOMARKER	01 May 2014	61/986,933			01 May 2015	Expired
US2013/276	US	PSP	SARILUMAB (ANTI-IL6R) BIOMARKER	31 Oct 2014	62,073638			31 Oct 2015	PENDING
US2013/276	WO	PCT	SARILUMAB (ANTI-IL6R) BIOMARKER	29 Jan 2015	PCT/US2015/013588			29 Jan 2035	PENDING
US2013/294	EP	EPA	METHODS OF TREATING ASTHMA - DRI12544	15 Sep 2014	14306413.7				ABANDONED
US2013/294	US	NP	PHASE 2B CLINICAL TRIAL METHODS OF TREATING ASTHMA - DRI12544	20 Feb 2015	14/627,728			20 Feb 2035	PENDING
US2013/294	US	PSP	PHASE 2B CLINICAL TRIAL METHODS OF TREATING ASTHMA - DRI12544	21 Feb 2014	61/943,019			21 Feb 2015	Expired
US2013/294	US	PSP	PHASE 2B CLINICAL TRIAL METHODS OF TREATING ASTHMA - DRI12544	10 Nov 2014	62/077,669			10 Nov 2015	PENDING
US2013/294	WO	PCT	PHASE 2B CLINICAL TRIAL METHODS OF TREATING ASTHMA - DRI12544	20 Feb 2015	PCT/US2015/016852			20 Feb 2035	PENDING
US2014/010	EP	EPA	PHASE 2B CLINICAL TRIAL COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	05 Sep 2014	14306366.7				ABANDONED
US2014/010	US	PSP	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	22 Nov 2013	61/907,796				ABANDONED
US2014/010	US	PSP	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	06 Jun 2014	62/008,787			06 Jun 2015	Expired
US2014/010	WO	PCT	COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND METHODS OF USING SAME	21 Nov 2014	PCT/US2014/066856			21 Nov 2034	PENDING
US2014/015	EP	EPA	METHODS FOR TREATING PATIENTS WITH HYPERCHOLESTEROLEMIA THAT IS NOT ADEQUATELY CONTROLLED BY MODERATE-DOSE STATIN THERAPY	29 Oct 2014	14306729.6				ABANDONED

EXHIBIT A
(Sanofi to Sanofi Biotechnology)

Sanofi No.	Country	Type	Title	Filing Date	Filing No.	Grant Date	Patent No.	Expiry Date	Status
US2014/015	EP	EPA	METHODS FOR TREATING PATIENTS WITH HYPERCHOLESTEROLEMIA THAT IS NOT ADEQUATELY CONTROLLED BY MODERATE-DOSE STATIN THERAPY	28 Oct 2014	143067,15.5				ABANDONED
US2014/015	US	NP	METHODS FOR TREATING PATIENTS WITH HYPERCHOLESTEROLEMIA THAT IS NOT ADEQUATELY CONTROLLED BY MODERATE-DOSE STATIN THERAPY	12 Feb 2015	14/621,000			12 Feb 2035	PENDING
US2014/015	US	PSP	METHODS FOR TREATING PATIENTS WITH HYPERCHOLESTEROLEMIA THAT IS NOT ADEQUATELY CONTROLLED BY MODERATE-DOSE STATIN THERAPY	19 May 2014	62/000,162			19 May 2015	Expired
US2014/015	US	PSP	METHODS FOR TREATING PATIENTS WITH HYPERCHOLESTEROLEMIA THAT IS NOT ADEQUATELY CONTROLLED BY MODERATE-DOSE STATIN THERAPY	14 Feb 2014	61/939,857			14 Feb 2015	Expired
US2014/015	US	PSP	METHODS FOR TREATING PATIENTS WITH HYPERCHOLESTEROLEMIA THAT IS NOT ADEQUATELY CONTROLLED BY MODERATE-DOSE STATIN THERAPY	16 Jul 2014	62/025,094			16 Jul 2015	Expired
US2014/015	US	PSP	METHODS FOR TREATING PATIENTS WITH HYPERCHOLESTEROLEMIA THAT IS NOT ADEQUATELY CONTROLLED BY MODERATE-DOSE STATIN THERAPY	18 Sep 2014	62/052,227			18 Sep 2015	PENDING
US2014/015	WO	PCT	METHODS FOR TREATING PATIENTS WITH HYPERCHOLESTEROLEMIA THAT IS NOT ADEQUATELY CONTROLLED BY MODERATE-DOSE STATIN THERAPY	12 Feb 2015	PCT/US2015/015633			12 Feb 2035	PENDING
US2014/017	EP	EPA	METHODS FOR TREATING PATIENTS WITH HYPERCHOLESTEROLEMIA	26 Feb 2015	15305292.3				ABANDONED
US2014/017	US	NP	METHODS FOR TREATING PATIENTS WITH HYPERCHOLESTEROLEMIA	13 Mar 2015	14/657,186			13 Mar 2035	PENDING
US2014/017	US	PSP	METHODS FOR TREATING PATIENTS WITH HYPERCHOLESTEROLEMIA	17 Mar 2014	61/954,107			17 Mar 2015	Expired
US2014/017	US	PSP	METHODS FOR TREATING PATIENTS WITH HYPERCHOLESTEROLEMIA	17 Nov 2014	62/080,709			17 Nov 2015	PENDING
US2014/017	WO	PCT	METHODS FOR TREATING PATIENTS WITH HYPERCHOLESTEROLEMIA	15 Mar 2015	PCT/EP2015/055369			15 Mar 2035	PENDING
US2014/018	EP	EPA	METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA	23 Mar 2015	15305419.2				ABANDONED

EXHIBIT A
(Sanofi to Sanofi Biotechnology)

Sanofi No.	Country	Type	Title	Filing Date	Filing No.	Grant Date	Patent No.	Expiry Date	Status
US2014/018	US	NP	METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA	16 Jul 2015	14/801,384			16 Jul 2035	PENDING
US2014/018	US	PSP	METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA	28 Aug 2014	62/043,144			28 Aug 2015	Expired
US2014/018	US	PSP	METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA	16 Jul 2014	62/025,362			13 Jul 2015	PENDING
US2014/018	US	PSP	METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA	17 Nov 2014	62/080,717			17 Nov 2015	PENDING
US2014/018	WO	PCT	METHODS FOR TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA	16 Jul 2015	PCT/US2015/040754			16 Jul 2035	PENDING
US2014/019	EP	EPA	METHODS FOR TREATING PATIENTS WITH HYPERCHOLESTEROLEMIA AT HIGH CARDIOVASCULAR RISK	29 May 2015	EP1305830.0				ABANDONED
US2014/019	US	NP	METHODS FOR TREATING PATIENTS WITH HYPERCHOLESTEROLEMIA AT HIGH CARDIOVASCULAR RISK	16 Jul 2015	14/801,392			16 Jul 2035	PENDING
US2014/019	US	PSP	METHODS FOR TREATING PATIENTS WITH HYPERCHOLESTEROLEMIA AT HIGH CARDIOVASCULAR RISK	28 Aug 2014	62/043,167			28 Aug 2015	Expired
US2014/019	US	PSP	METHODS FOR TREATING PATIENTS WITH HYPERCHOLESTEROLEMIA AT HIGH CARDIOVASCULAR RISK	17 Nov 2014	62/080,725			17 Nov 2015	PENDING
US2014/019	US	PSP	METHODS FOR TREATING PATIENTS WITH HYPERCHOLESTEROLEMIA AT HIGH CARDIOVASCULAR RISK	16 Jul 2014	62/025,371			13 Jul 2015	PENDING
US2014/019	US	PSP	METHODS FOR TREATING PATIENTS WITH HYPERCHOLESTEROLEMIA AT HIGH CARDIOVASCULAR RISK	13 Mar 2015	62/132,709			13 Mar 2016	PENDING
US2014/019	WO	PCT	METHODS FOR TREATING PATIENTS WITH HYPERCHOLESTEROLEMIA AT HIGH CARDIOVASCULAR RISK	16 Jul 2015	PCT/US2015/040765			16 Jul 2035	PENDING
US2014/021	EP	EPA	METHODS FOR TREATING SKIN INFECTION BY ADMINISTERING AN IL-4R ANTAGONIST	24 Sep 2014	14306476.4				ABANDONED
US2014/021	US	NP	METHODS FOR TREATING SKIN INFECTION BY ADMINISTERING AN IL-4R ANTAGONIST	26 Feb 2015	14/632,988			26 Feb 2035	PENDING
US2014/021	US	PSP	METHODS FOR TREATING SKIN INFECTION BY ADMINISTERING AN IL-4R ANTAGONIST	13 Mar 2014	61/952,245			13 Mar 2015	Expired
US2014/021	US	PSP	METHODS FOR TREATING SKIN INFECTION BY ADMINISTERING AN IL-4R ANTAGONIST	30 Apr 2014	61/986,371			30 Apr 2015	Expired

EXHIBIT A
(Sanofi to Sanofi Biotechnology)

Sanofi No.	Country	Type	Title	Filing Date	Filing No.	Grant Date	Patent No.	Expiry Date	Status
US2014/021	US	PSP	METHODS FOR TREATING SKIN INFECTION BY ADMINISTERING AN IL-4R ANTAGONIST	28 Feb 2014	61/946,237			28 Feb 2015	Expired
US2014/021	US	PSP	METHODS FOR TREATING SKIN INFECTION BY ADMINISTERING AN IL-4R ANTAGONIST	06 Jan 2015	62/100,128			06 Jan 2016	PENDING
US2014/021	WO	PCT	METHODS FOR TREATING SKIN INFECTION BY ADMINISTERING AN IL-4R ANTAGONIST	26 Feb 2015	PCT/US2015/017834			26 Feb 2035	PENDING
US2014/026	EP	EPA	USE OF ANTI-PCSK9 INHIBITORS TO REDUCE CARDIOVASCULAR RISK	26 Feb 2015	15305293.1				ABANDONED
US2014/026	US	NP	USE OF ANTI-PCSK9 INHIBITORS TO REDUCE CARDIOVASCULAR RISK	13 Mar 2015	14/657,192			13 Mar 2035	PENDING
US2014/026	US	PSP	USE OF ANTI-PCSK9 INHIBITORS TO REDUCE CARDIOVASCULAR RISK	16 Jul 2014	62/025,400			16 Jul 2015	Expired
US2014/026	US	PSP	USE OF ANTI-PCSK9 INHIBITORS TO REDUCE CARDIOVASCULAR RISK	17 Mar 2014	61/954,094			17 Mar 2015	Expired
US2014/026	US	PSP	USE OF ANTI-PCSK9 INHIBITORS TO REDUCE CARDIOVASCULAR RISK	28 Aug 2014	62/043,182			28 Aug 2015	Expired
US2014/026	WO	PCT	USE OF ANTI-PCSK9 INHIBITORS TO REDUCE CARDIOVASCULAR RISK	13 Mar 2015	PCT/US2015/020564			13 Mar 2035	PENDING
US2014/094	EP	EPA	METHODS OF TREATING NASAL POLYPOSIS BY ADMINISTERING AN IL-4R ANTAGONIST						TO BE FILED
US2014/094	US	NP	METHODS OF TREATING NASAL POLYPOSIS BY ADMINISTERING AN IL-4R ANTAGONIST						TO BE FILED
US2014/094	US	PSP	METHODS OF TREATING NASAL POLYPOSIS BY ADMINISTERING AN IL-4R ANTAGONIST	14 Nov 2014	62/080,092			14 Nov 2015	PENDING
US2014/094	US	PSP	METHODS OF TREATING NASAL POLYPOSIS BY ADMINISTERING AN IL-4R ANTAGONIST	31 Jul 2015	62/199,305			31 Jul 2016	PENDING
US2014/094	US	PSP	METHODS OF TREATING NASAL POLYPOSIS BY ADMINISTERING AN IL-4R ANTAGONIST	08 May 2015	62/158,832			08 May 2016	PENDING
US2014/094	US	PSP	METHODS OF TREATING NASAL POLYPOSIS BY ADMINISTERING AN IL-4R ANTAGONIST	24 Nov 2014	62/083,821			24 Nov 2015	PENDING
US2014/094	WO	PCT	METHODS OF TREATING NASAL POLYPOSIS BY ADMINISTERING AN IL-4R ANTAGONIST						TO BE FILED

PATENT

REEL: 041749 FRAME: 0583

RECORDED: 03/27/2017